View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 10, 2017updated 13 Jul 2022 10:08am

Mundipharma EDO initiates Phase I/II oncology trial of tinostamustine in US

Switzerland-based Mundipharma EDO has initiated a Phase I/II clinical trial of tinostamustine (EDO-S101) to treat patients with advanced solid tumours in the US.

Switzerland-based Mundipharma EDO has initiated a Phase I/II clinical trial of tinostamustine (EDO-S101) to treat patients with advanced solid tumours in the US.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Tinostamustine is an alkylating deacetylase inhibiting (AK-DACi) molecule that has demonstrated an ability to improve access to DNA strands in cancer cells, break them and counteract damage repair during preclinical studies.

The multi-centre Phase I/II trial is being conducted at Stanford University, Cedars Sinai Medical Centre in Los Angeles and the Mayo Clinic in Scottsdale.

Mundipharma EDO CEO Dr Thomas Mehrling said: “Following the initial Phase I study in haematological malignancies, I am delighted that EDO is now embarking on a further clinical trial in solid tumours.

“Breaking through resistance is essential if we are to continue to address unmet needs in oncology.

“This is a key step in the investigation of a first-in-class treatment, which we hope will prove a vital addition for patients with limited current options.”

“This is a key step in the investigation of a first-in-class treatment, which we hope will prove a vital addition for patients with limited current options.”

The primary objective of the Phase I part of the trial is evaluation of safety, tolerability, maximum-tolerated dose (MTD) and recommended Phase II dose (RP2D) of tinostamustine as a monotherapy.

While the trial’s secondary objective is pharmacokinetic (PK) profile, the exploratory objective is extent of gene expression changes in tumour samples with anti-tumour activity.

The Phase II part of the trial will include cohorts of patients with specific solid tumours such as small cell lung cancer (SCLC), soft tissue sarcoma (STS), non-KIT gastrointestinal stromal tumours (GIST), triple negative breast cancer (TNBC) and ovarian cancer.

The primary objectives are objective response rate (ORR) and clinical benefit rate (CBR), while the secondary objectives include safety, progression-free survival, overall survival, duration of response and PK profiles.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena